Related Experiment Video
Updated: Mar 20, 2026
Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
Published on: November 14, 2016
Progressive Multiple Sclerosis
Purpose Of Review:
Many therapeutic advances for relapsing-remitting multiple sclerosis (MS) have occurred in the past 25 years. Although similar advances in disease-modifying therapies have not been realized in progressive MS, many symptomatic therapeutic strategies can benefit patients with progressive MS. Few guidelines exist for management of patients with progressive MS.
Recent Findings:
The classification of progressive MS was revised in 2013 to include a description of inflammatory disease activity determined by clinical relapses or imaging findings. Developing knowledge about the pathogenesis of progressive MS and the role of comorbidities in modifying the disease course has implications for the clinical management of patients with progressive MS as well as for clinical trial design. Current and upcoming clinical trials will assess a wide range of interventions, including immunomodulatory agents, putative neuroprotective molecules, stem cell therapy, nutrition, and rehabilitation techniques.
Summary:
None of the therapies currently approved for use in relapsing-remitting MS have been shown to slow the gradual progression of disability that occurs in the absence of recent relapses or changes in MRI. A multidisciplinary approach is needed to address the many symptoms that impact quality of life for patients with progressive MS.
Insights
Therapeutic advances for progressive multiple sclerosis (MS) are limited, but symptomatic treatments can improve quality of life. A multidisciplinary approach is crucial for managing progressive MS symptoms.
Area of Science:
- Neurology
- Immunology
- Clinical Therapeutics
Background:
- Relapsing-remitting multiple sclerosis (MS) has seen significant therapeutic progress, unlike progressive MS.
- Current management strategies for progressive MS are primarily symptomatic, with limited disease-modifying options.
Observation:
- The 2013 revision of progressive MS classification incorporates inflammatory activity via relapses or imaging.
- Understanding progressive MS pathogenesis and comorbidity impact is vital for clinical management and trial design.
Findings:
- No current therapies approved for relapsing-remitting MS effectively slow disability progression in progressive MS.
- Research is exploring immunomodulatory agents, neuroprotective molecules, stem cells, nutrition, and rehabilitation.
Implications:
- A comprehensive, multidisciplinary approach is essential for managing progressive MS symptoms and enhancing patient quality of life.
- Future clinical trials will investigate a broad spectrum of interventions for progressive MS.
Related Concept Videos
01:15Parkinson's Disease: Overview
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...